![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123222.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123239.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-124151.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123316.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123333.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123354.png)
![](https://inheritedcancer.net/wp-content/uploads/Screenshot-2024-08-06-123429.png)
The American Society of Clinical Oncology (ASCO) just released new guidelines for the selection of germline genetic testing panels in patients with cancer. Items addressed include ⤸
What elements are most important in the collection of family history?
🧬 Details of cancers in first- and second-degree relatives and the patient’s ethnicity.
When and how to use multigene panel testing when indicated?
🧬 When more than one gene is relevant based on personal and/or family history, multigene panel testing should be offered.
Which genes to test based on cancer type?
🧬 Table 1 outlines genes based on cancer type, including those more versus less strongly recommended.
Among those with tumor testing, which patients should be offered germline testing?
🧬 Any patient who meets criteria for germline genetic testing should be offered germline testing regardless of results from tumor testing.
🧬 Even those not meeting criteria based on personal or family history who have a mutation identified through tumor testing in a gene listed in Table 2 under the outlined circumstances should be offered germline testing.
Learn more by reading the full article at: https://ascopubs.org/doi/10.1200/JCO.24.00662
There is also a related clinical insights article available at: https://ascopubs.org/doi/full/10.1200/OP.24.00278
To stay updated, we encourage you to download the ASCO Guidelines app to easily access recommendations in the future.
Reference: Tung, et al. J Clin Oncol. 2024:JCO2400662. PMID: 38759122.